| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Merck & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$113.60 |
| 52 Week High | US$131.67 |
| 52 Week Low | US$103.30 |
| Beta | 0.40 |
| 11 Month Change | 0% |
| 3 Month Change | -13.72% |
| 1 Year Change | 4.94% |
| 33 Year Change | 47.09% |
| 5 Year Change | n/a |
| Change since IPO | 101.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRK | PE Pharmaceuticals | PE Market | |
|---|---|---|---|
| 7D | 0% | -4.4% | 0.03% |
| 1Y | 4.9% | -14.0% | 5.1% |
Return vs Industry: MRK exceeded the PE Pharmaceuticals industry which returned -14% over the past year.
Return vs Market: MRK matched the PE Market which returned 5.1% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 2.6% |
| 10% most volatile stocks in PE Market | 5.6% |
| 10% least volatile stocks in PE Market | 0.9% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months.
Volatility Over Time: MRK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 71,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Merck & Co., Inc. Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market cap | US$297.00b |
| Earnings (TTM) | US$13.74b |
| Revenue (TTM) | US$62.48b |
21.6x
P/E Ratio4.8x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | US$62.48b |
| Cost of Revenue | US$15.13b |
| Gross Profit | US$47.35b |
| Other Expenses | US$33.62b |
| Earnings | US$13.74b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | 5.42 |
| Gross Margin | 75.79% |
| Net Profit Margin | 21.98% |
| Debt/Equity Ratio | 86.6% |
How did MRK perform over the long term?
See historical performance and comparison